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It is now well established that the major virulence factors of C. difficile are the two toxins A and B. However,
the organism possesses an array of other putative virulence factors that may be important for localisation
within the colon, and in evasion of the immune system. It has been observed that certain types of C. difficile are
more commonly found causing disease than others, and this seems to be independent of toxin production.
Is this simply a reflection of their abundance in the hospital environment, or is it due to their virulence
determinants? This review covers our current knowledge of the modes of action of toxins A and B at the
cellular and molecular level. Many unanswered questions are posed that require answers before we can
fully understand the pathogenic mechanisms of the organism and be in a position to manage better the
spectrum of diseases it causes.
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INTRODUCTION
The spectrum of disease and its pathology
Clostridium difficile is a commonly isolated organism from fecal
specimens obtained from neonates and the elderly. Often its
carriage is asymptomatic, and this is especially true in the
neonate. However, in the elderly, it is often associated with
disease symptoms that range from mild self-limiting diarrhea to
serious diarrhea, with or without pseudomembrane formation
(pseudomembranous colitis; Figure 1), and with the possibility
of life-threatening complications such as toxic megacolon,
perforation and peritonitis.
Antibiotics and the normal gastrointestinalmicrobiota
The proposed sequence of events that precipitate C. difficile
disease are as follows: on exposure of the gut to antibiotics, the
microbiota becomes disrupted and colonisation resistance is
compromised. The gut is then susceptible to colonisation by
+C. difficile. The organism is acquired in most cases from an
exogenous source – either from an infected individual, from a
contaminated health care worker, or indirectly from a con-
taminated environment. Once ingested C. difficile evades
immune responses, multiplies in the colon and produces toxins
A and B. The characteristic pathology then results.
Virulence factors of C. difficile
C. difficile is typical of its genus: it is an anaerobic, Gram-
positive, spore-forming bacillus that produces toxins. The two
toxins A and B are commonly referred to as the enterotoxin
(toxin A) and the cytotoxin (toxin B). This terminology
originated from the observed actions of these toxins: demon-
stration of fluid accumulation in intestinal loop models and the
cytopathic effects on tissue culture monolayers, respectively.
These investigations were done before the action at the mole-
cular level was well understood. However, as is described below,
both toxins have a great deal in common.
Other toxins have been identified, in particular the bipartite,
ADP-ribosylating toxin, which is described in more detail in an
accompanying review [1].
The role of other virulence factors is much more speculative.
Adhesins have been proposed as being important but their
relevance in the colon, and their identity, is still not assured.
Several extracellular enzymes are produced that do have effects
in vitro, but their role in pathogenesis is not well defined.
Presumably these enzymes do have a role in the normal
physiological processes in the gastrointestinal (GI) tract and
may be crucial for the normal survival of the organism, giving it
an advantage when the normal GI microbiota have been
disturbed following antibiotic usage.
C. difficile is somewhat unusual in that it has an outer cell coat
termed the S-layer. This consists of two polypeptides that
together form a regular, crystalline array over the whole surface
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of the bacterium. The S-layer is proposed to be a virulence
factor and is discussed in more detail later.
THE TOXINS AND HOW THEY WORK
The majority of toxigenic strains produce both the A and B
toxins. In summary, their mode of action is similar: they are
endocytosed by the cell, they affect the actin cytoskeleton and
they result in cell death. They also induce the production of
tumor necrosis factor-alpha (TNFa) and proinflammatory
interleukins (ILs) which contribute to the associated inflam-
matory response and pseudomembrane formation.
Toxin A causes necrosis, increased intestinal permeability and
inhibition of protein synthesis. Toxin A also affects phospho-
lipase A2, thereby producing prostaglandins and leukotrienes.
Toxin A damages villous tips and brush border membranes
and complete erosion of the mucosa may result. A viscous,
bloody fluid is produced in response to this tissue damage.
However, in the case of toxin B, there is no noticeable enter-
otoxic activity but it is lethal to cells in vitro. Therefore Toxin B
is thought to become effective once the gut wall has been
damaged.
The structure of toxins A and B
The two major toxins are coded on a pathogenicity locus
(Figure 2). The products of transcription and translation are
extremely large single-chain peptides with molecular masses of
308 kDa for toxin A and 270 kDa for toxin B [3]. There are
three functional domains to these toxins (Figure 3). The toxins
Figure1 Pseudomembranous colitis, post-mor-
tem specimen.
Figure 2 The pathogenicity locus ofClostridium difficile (modified from ref. 2).
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are 50% identical at the amino acid level and have similar
primary structures. Hoffman et al. [4] noted that the enzyme
and cytotoxic activity of toxin B was to be found at the toxin’s
N-terminus, which also holds the enzyme and cytotoxic activ-
ity of toxin A. The middle section of both toxins includes a
transmembrane domain, which is thought to encode for the
translocation of the toxin into the cytosol, but this has yet to be
proven [5]. The C-terminal of the toxin encompasses the
receptor-binding domain and is constructed of repetitive pep-
tide elements.
Action of toxins A and B
The carboxy terminal of toxin A forms binding domains for
carbohydrate structures that occur on the surface of the epithe-
lium. Toxin B binds to cells that are not covered by a thick
carbohydrate matrix. They then enter the cell by endocytosis
[6]. Both toxins require passage through an acidic intracellular
compartment in order to intoxicate cells. This route is not
known for toxin A, but toxin B is believed to be delivered by
lysosomes and is then released into the cytosol.
The major effect of toxins A and B is the disruption of the
actin cytoskeleton. Cells intoxicated by these proteins show a
retraction of cell processes and a rounding of the cell body. This
is due to the disassembly of filamentous F-actin and an increase
in G-actin prior to cell rounding [7]. Very few toxin molecules
are required to produce cell rounding. It has been proposed that
C. difficile toxins act enzymatically within cells, modifying
proteins that regulate actin polymerisation and fiber assembly.
These proteins are known as the Rho proteins, a subfamily of
the Ras-family of GTPases [7]. The mechanisms of action of
either toxin are summarised in Figure 4.
In the diseased state, the colonic epithelium is the major
target of C. difficile toxins. They cause disruption of the barrier
function by opening the tight junctions. This effect is not
merely caused by the breakdown of actin filaments but by
the inactivation of the Rho function to regulate tight junction
complexes. These barrier-disrupting effects of toxin A and B
increase the colonic permeability, the basis of watery diarrhea,
which is a typical feature of C. difficile antibiotic-associated
diarrhea (Figure 5).
Apoptosis of enterocytes
A study by Fiorentini et al. [8] provided the first experimental
evidence that cultured intestinal cells exposed to toxin B
showed all the features of apoptosis. A study by Mahida et al.
[9] showed the same effect being caused by toxin A. All cells
undergo apoptosis at some point, as this controlled cell death is
an important feature of tissue development and homeostasis,
keeping the number of functional cells in balance in the body.
Apoptosis can be identified as being different from cell necrosis
by distinct morphological alterations. These alterations come in
the form of nuclear condensation and fragmentation, cell
shrinkage and the absence of inflammation [8]. In monolayers
of cell cultures, apoptosis can be induced by inhibition of cell
adhesion and of anchorage-dependent cell spreading. Toxin B is
capable of both inhibition of anchorage and cell spreading.
Figure 3 The structure of Clostridium difficile toxins A and B (modified from ref. 2).
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 421–427
Poxton et al The pathogenicity of C. difficile 423
However, it was found that apoptosis was not only caused
by toxin B inhibiting cell adhesion due to actin depolymerisa-
tion but that Rho proteins themselves may play an important
role in the regulation of apoptosis under normal conditions [8].
Toxin B, therefore, can be seen as an inducer and not as the
cause of apoptosis. It is the effects of toxin B on the Rho
proteins that cause the abnormal activation of the apoptotic
system. With toxin A, it is thought that apoptosis occurs because
the epithelial cells are denied anchorage to the basement
membrane.
Figure 4 Simplified scheme for the action of
Clostridium difficile toxins on cells (modified
from ref. 6).
Figure 5 Actions of Clostridium difficile toxins A and B on intestinal epithelium (modified from ref. 6).
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Differences in cytotoxic potencies in toxin A and B
To cause pseudomembranous colitis, both toxins A and B are
normally required. The two toxins intoxicate cultured cell lines
by the same mechanism but when it comes to potency, toxin B
is around a 1000 times more potent than toxin A. Toxin B has at
least a 100-fold higher enzymatic activity than toxin A, and this
is believed to be the main determinant in the difference in
cytotoxic potency.
Due to the low enzymatic potency of toxin A, it has been
proposed that glucosylation of the Rho-proteins may not be the
primary in vivo effect of this toxin. Some believe neuronal
involvement may be a possible answer to enterotoxic effects of
toxin A [10]. The suggestion is that the pathophysiological
process is triggered by a transepithelial signal to neuroimmune
cells that is triggered by the binding of toxin A to the intestinal
mucosa. The modification of Rho proteins by toxin A and B
would then play a secondary, but important, role in exacerbat-
ing mucosal inflammation and destruction. This theory agrees
with an experiment done by Riegler et al. [11], where toxin B
was shown to be more potent than toxin A in damaging human
colonic epithelium in vitro. The mucosal strips were devoid of
enteric nerves and thus toxin B was shown to be 10 times more
effective in causing damage.
ACTIVATION OF THE IMMUNE SYSTEM
Colitis is characterised by a massive influx of neutrophils into
the colonic mucosa, and in pseudomembranous colitis there is
an acute inflammatory infiltrate with microabscesses and pseu-
domembranes rich in neutrophils [12]. The movement of
neutrophils from circulating blood to the site of injury is a
crucial event during the inflammatory process. IL-1, IL-8, TNF
and leukotriene B4 are products of resident cells and are thought
to be involved in neutrophil infiltration into the inflamed
site.
Both toxins stimulate the release of TNFa from cultured
monocytes. Toxin B was again found to be 1000 times more
potent than toxin A in this system [12]. Both toxins also activate
monocytes and macrophages in the lamina propria in vitro to
release IL-8. This causes neutrophil extravasation and tissue
infiltration by creating a chemotactic gradient that induces
neutrophil migration to the site of mucosal inflammation
[13]. Using mast cell-deficient mice, Pothoulakis et al. [14]
demonstrated the importance of mast cells for neutrophil
recruitment and fluid secretion induced by toxin A in vivo.
Isolated mast cells were also shown to respond to toxin A by
releasing TNFa. This activation could be inhibited with a
specific antagonist to substance P. Substance P is a peptide
found in gut tissue and in the CNS that acts as a neurotrans-
mitter. This suggests that toxin A activates mast cells via the
release of substance P from adjacent sensory neurons [15].
This can also be seen as another point marking toxin A activity
with neuronal stimuli.
Neutrophil recruitment appears to be an essential step in the
pathogenesis of C. difficile toxin-induced intestinal injury as
biopsy specimens from patients with C. difficile colitis show
marked vascular congestion, neutrophil infiltration of the
lamina propria and inflammation. Although it was shown by
Calderon et al. [15] that toxin A was able to activate neutrophils,
mast cells and macrophages in vitro, there is still some spec-
ulation as to how this works in vivo due to the large size of the
toxin. Toxin A can cause detachment and apoptosis of enter-
ocytes and so, in this disrupted epithelium, toxin A may diffuse
and interact with the inflammatory cells in the lamina propria.
Also, localised areas of injury and inflammation may result from
cell rounding that would cause breaches in the colonic epithe-
lium through which tiny amounts of toxin A and B can pass.
These small amounts cannot directly activate neutrophils but
may activate tissue macrophages to produce IL-8 and other
proinflammatory cytokines. Once the inflammatory cascade is
initiated, it can result in a marked acute inflammatory cell
infiltration, further mucosal injury and focal pseudomembrane
formation [13].
IMMUNIT Y AND HOST DEFENCES
Innatemechanisms
Probably the best defence against infection by C. difficile is an
intact normal bowel microbiota – preventing establishment of
C. difficile by colonisation resistance [16]. Normal gut motility
and an effective gastric acid barrier are no doubt also important
[17].
Acquired immunemechanisms
Experiments with hamsters suggest that systemic IgG to toxin A
– induced by vaccination – is protective [18], and secretory
(IgA) antibodies to toxins A and B may be protective as
demonstrated by protecting hamsters fed milk from immunised
mothers. However, this is an area still requiring a great deal of
work, especially to determine the potential for immunisation in
humans [17].
PHENOT YP IC VARIATION
There is a degree of phenotypic variation between strains of C.
difficile. In respect to pathogenicity, it seems that non-toxigenic
strains can be considered non-pathogenic or avirulent. How-
ever, it is well accepted that there are degrees of virulence
between strains. The discovery of virulent strains of toxin
A-negative/toxin B-positive phenotype indicated that toxin
A was not essential for virulence. How these strains cause
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disease is not readily apparent but based on the discussion above
there is so much similarity between toxins A and B that once
there is any damage to the mucosal cell layer then either could
cause symptoms.
In common with several pathogens, C. difficile has an S-layer
covering its entire surface. We have proposed recently that this
might have a role in virulence [19]. There is certainly a degree of
correlation between serotype and virulence that is independent
of toxin production: certain serotypes are more often associated
with disease. Serotype correlates well with S-type and also to
ribotype [19 and unpublished data]. Figure 6 shows an example
of the S-layer proteins extracted from different strains with
guanidine hydrochloride, and each strain belongs to a different
serotype.
UNANSWERED QUESTIONS
Despite knowing a great deal about the mode of action of the
major toxins, and understanding the epidemiology of the
pathogen, many questions remain unanswered. For some, there
are partial answers but, in the opinion of the authors, none of
the following are yet answered fully:
Why are infants not affected?
Do the toxins have any role in the healthy intestine?
Is immunity to cell surface components protective – would
whole cell vaccines be a possibility?
Why are some types much more virulent than others?
What is the molecular basis of serotype?
Why are there so many S-types?
What is the genetic basis for S-layer peptide variation?
It is generally agreed that C. difficile-associated disease is
increasing worldwide, and our last question, ‘Have super
strains evolved?’, remains unanswered. Is the increase purely
because the organism – as spores – becomes persistent in the
environment of the elderly patient, where it is maintained
by constantly being passaged in susceptible individuals, or
have previously harmless strains from neonates acquired viru-
lence attributes, and are more persistent, more virulent strains
evolving?
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